GlassScriptPhysician profile
Andrew W Pieleck
NPI 1821226937
$3,016.38
in general payments reported to CMS, 2019-2025
25 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $543 · 2021: $238 · 2022: $424 · 2023: $694 · 2024: $336 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.18 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $513.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $469.56 | 2021-2025 | |
| Pfizer INC. | $399.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $290.59 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $222.36 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $207.25 | 2020-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $112.68 | 2019-2024 | Gardasil 9, Vaxneuvance, M-M-R II |
| Sanofi Pasteur INC. | $110.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $98.18 | 2019-2023 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $72.51 | 2023 | Inspire |
| Phathom Pharmaceuticals, INC. | $70.30 | 2024 | Voquezna |
| Exact Sciences Corporation | $60.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bioventus LLC | $45.47 | 2025 | Durolane |
| Supernus Pharmaceuticals, INC. | $43.44 | 2021 | |
| Amarin Pharma, INC. | $42.63 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $41.49 | 2025 | Rexulti |
| Abbott Laboratories | $41.45 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.38 | 2019 | |
| Phadia US INC. | $35.09 | 2019-2020 | |
| Linus Health, INC. | $20.48 | 2023 | |
| Horizon Therapeutics Plc | $17.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.39 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.37 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.17 | 2023 | Quviviq |
| Genentech USA, INC. | $15.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pieleck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.